Jazz Pharmaceuticals plc(JAZZ)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Jazz Pharmaceuticals plc (JAZZ) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JAZZ at 70.8/100 on a 32-signal composite quality model, placing it at rank #208 of 2,961 stocks — the top 10% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Jazz Pharmaceuticals plc reports quarterly revenue of $1.2B, net income of $192.8M, free cash flow of $397.6M. Top institutional holders of JAZZ by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. JAZZ trades on the Nasdaq exchange and files with the SEC under CIK 1232524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JAZZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jazz Pharmaceuticals plc directly from SEC EDGAR.
AI Quality Score
70.8/100
AI Rank
#208
Revenue
$1.2B
Net Income
$192.8M
Free Cash Flow
$397.6M
JAZZ key financials by period
Jazz Pharmaceuticals plc reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$4.3B
$-356.1M
-10.1%
FY 2024
10-K
$4.1B
$560.1M
17.6%
FY 2023
10-K
$3.8B
$414.8M
15.1%
FY 2022
10-K
$3.7B
$-224.1M
-1.8%
FY 2021
10-K
$3.1B
$-329.7M
5.5%
FY 2020
10-K
$2.4B
$238.6M
16.0%
Institutions holding JAZZ
Institutional investors reporting a position in Jazz Pharmaceuticals plc on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Jazz Pharmaceuticals reported H1 2026 total revenues of $2.28B (+17% YoY), driven by Xywav growth of +16% YoY and oncology revenue expansion of +38% YoY, with operating income of $584.8M versus loss of $742.3M in prior year.
Biggest Revenue Drivers
Sleep disorders (Xywav, Xyrem)$941.1M+13% YoY
Xywav volume growth of 12% and higher selling price; narcolepsy patients increased 6% to 11,275; idiopathic hypersomnia patients increased 26% to 5,850.
Epilepsy (Epidiolex/Epidyolex)$541.9M+15% YoY
Volume growth of 13% driven by increased demand and higher average selling price, partially offset by higher deductions.
Biggest Revenue Drivers
Total revenue: $2.28B+17% YoY
Sleep disorders (Xywav, Xyrem)$941.1M+13% YoY
Xywav volume growth of 12% and higher selling price; narcolepsy patients increased 6% to 11,275; idiopathic hypersomnia patients increased 26% to 5,850.
Epilepsy (Epidiolex/Epidyolex)$541.9M+15% YoY
Volume growth of 13% driven by increased demand and higher average selling price, partially offset by higher deductions.
Oncology$695.7M+38% YoY
Zepzelca +50% YoY on adoption in first-line maintenance setting; Modeyso contributed $89.6M post-launch in August 2025; Ziihera +157% on launch in December 2024.
Royalties and contract revenues$95.8M-19% YoY
Decrease in royalty revenue from Hikma due to reduced royalty rate on high-sodium oxybate authorized generic sales.
Largest Expense Items
Research and development$403.5M+9% YoY
Higher clinical studies and outside services costs related to zanidatamab and dordaviprone; personnel expenses increased $17.7M.
Selling, general and administrative$741.9M-15% YoY
Decreased due to Xyrem antitrust litigation settlements of $172M incurred in prior year, offset by increased marketing investment of $22.3M and compensation-related expenses.
Intangible asset amortization$342.3M+8% YoY
Increase primarily due to impact of foreign currency translation on sterling assets.
Cost of product sales (excluding amortization)$250.5M+13% YoY
Higher royalty expenses driven by higher revenues and increased inventory provisions, offset by lower fair value step-up expense of $12.8M.
Watch Items from the Filing
Xywav faces material competition from generic high-sodium oxybate; Amneal and Ascent launched generics in March 2026; Lupin received tentative FDA approval; Tris Pharma filed 505(b)(2) NDA for both Xyrem and Xywav with 22 patent challenges pending.
Three customers represent significant concentration: ESSDS 41%, McKesson 11%, ASD 11% of total revenues; loss of any major distributor could materially impact sales.
Modeyso approval contingent on Phase 3 ACTION confirmatory trial verification; Ziihera accelerated approval dependent on Phase 3 HERIZON-BTC-302 confirmatory trial success; regulatory risk if trials fail.
Substantial debt of $4.4B principal outstanding; 2030 Notes became exchangeable during Q2 2026 (share price condition met); $1.0B principal due 2028 (Tranche B), $1.5B due 2029 (Secured Notes); refinancing risk.
Generated operating cash flow of $823.9M in H1 2026, up 59% YoY; cash and investments of $2.2B with $885M revolving credit facility available; strong liquidity to service debt.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
